JP2022151426A - Agents for treating upper respiratory inflammation - Google Patents
Agents for treating upper respiratory inflammation Download PDFInfo
- Publication number
- JP2022151426A JP2022151426A JP2021081950A JP2021081950A JP2022151426A JP 2022151426 A JP2022151426 A JP 2022151426A JP 2021081950 A JP2021081950 A JP 2021081950A JP 2021081950 A JP2021081950 A JP 2021081950A JP 2022151426 A JP2022151426 A JP 2022151426A
- Authority
- JP
- Japan
- Prior art keywords
- upper respiratory
- respiratory tract
- respiratory inflammation
- inflammation
- tract inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、上気道炎治療薬に関する。TECHNICAL FIELD The present invention relates to a therapeutic agent for upper respiratory inflammation.
上気道炎を根本的に治療する薬がない。There is no drug to cure upper respiratory tract inflammation fundamentally.
上気道炎治療薬を提供することを目的とする。The objective is to provide a remedy for upper respiratory tract inflammation.
本発明の目的を達成するため、次の構成を採用する。
上気道とは、呼吸の際に空気が通る道の鼻から気管手前までを言う。
上気道炎とは、上気道に細菌やウィルスなどの病原体が感染して起こる炎症ことであり、扁桃炎、咽頭炎、上咽頭炎、喉頭炎などがある。
変性剤を人体に投入することにより、炎症の原因である身体に侵入した細菌やウイルスのＤＮＡとＲＮＡを壊すことにより増殖を防ぎ、上気道炎の治療をす る。
細菌、ウイルス、などの炎症の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、細菌、ウイルスの増殖を防ぐことができるため、変性剤という上気道炎治療薬となる。
上気道炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。In order to achieve the object of the present invention, the following configuration is adopted.
The upper respiratory tract is the passageway through which air passes during respiration, from the nose to the front of the trachea.
Upper respiratory tract inflammation is inflammation caused by infection of pathogens such as bacteria and viruses in the upper respiratory tract, and includes tonsillitis, pharyngitis, epipharyngitis, laryngitis, and the like.
By injecting the denaturing agent into the human body, it destroys the DNA and RNA of bacteria and viruses that have invaded the body, which are the cause of inflammation, thereby preventing their proliferation and treating upper respiratory tract inflammation.
Inflammatory agents, such as bacteria and viruses, have nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, they release hydrogen ions and denature, breaking the hydrogen bond between bases of DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, it is possible to prevent the growth of bacteria and viruses.
There is also a method of administering to the human body as a liposome drug containing, as an active ingredient, a denaturing agent that targets the upper respiratory tract inflammation.
変性剤という上気道炎の治療薬を人体に投与することにより、上気道炎を治療する。代表的な変性剤は、尿素薬がある。Upper respiratory tract inflammation is treated by administering a therapeutic agent for upper respiratory tract inflammation called a denaturant to the human body. A representative denaturant is a urea drug.
変性剤という上気道炎の治療薬を口や鼻から注入する。
上気道炎の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、飲み薬として飲むか、注射により投与する。
代表的な変性剤は、尿素薬がある。A treatment for upper respiratory tract inflammation called a denaturant is injected through the mouth or nose.
As a liposomal drug containing a modifier that targets the upper respiratory tract inflammation as an active ingredient, it is taken orally or administered by injection.
A representative denaturant is a urea drug.
特願２０２０－１５５８６２Patent application 2020-155862
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081950A JP2022151426A (en) | 2021-03-26 | 2021-03-26 | Agents for treating upper respiratory inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081950A JP2022151426A (en) | 2021-03-26 | 2021-03-26 | Agents for treating upper respiratory inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022151426A true JP2022151426A (en) | 2022-10-07 |
Family
ID=83464215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081950A Pending JP2022151426A (en) | 2021-03-26 | 2021-03-26 | Agents for treating upper respiratory inflammation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022151426A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510657A (en) * | 1998-04-01 | 2002-04-09 | ノクタ・ピーティワイ・リミテッド | Methods of treating contaminated products and articles |
| JP2002516265A (en) * | 1998-05-27 | 2002-06-04 | ユーロセルティク ソシエテ アノニム | Formulations for applying anti-inflammatory agents, especially antiseptics and / or wound healing promoters, to the upper respiratory tract and / or ear |
-
2021
- 2021-03-26 JP JP2021081950A patent/JP2022151426A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510657A (en) * | 1998-04-01 | 2002-04-09 | ノクタ・ピーティワイ・リミテッド | Methods of treating contaminated products and articles |
| JP2002516265A (en) * | 1998-05-27 | 2002-06-04 | ユーロセルティク ソシエテ アノニム | Formulations for applying anti-inflammatory agents, especially antiseptics and / or wound healing promoters, to the upper respiratory tract and / or ear |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2587521A (en) | Treating & preventing microbial infections | |
| CA2942706C (en) | Rnase for use in treating or preventing viral infections | |
| JP6389172B2 (en) | Use of antithrombin in extracorporeal membrane oxygenator | |
| McLaurin | Treatment of infected ventricular shunts | |
| CN106938046A (en) | A kind of antibacterial peptide complex enzyme oral spray | |
| US9919034B2 (en) | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V | |
| JP2022151426A (en) | Agents for treating upper respiratory inflammation | |
| US20120156188A1 (en) | Chemical method for sexual sterilization and libido elimination in male mammals | |
| JP2022151427A (en) | Agents for treating esophagitis | |
| JP2022124985A (en) | Pneumonia therapeutic drugs | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151431A (en) | Agent for treating enteritis | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022151440A (en) | Agents for treating arthritis | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| JP2022140192A (en) | Therapeutic agent for bronchitis | |
| JP2022140193A (en) | Therapeutic agent for rheumatic diseases | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022151441A (en) | Agents for treating myositis and fasciitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |